PedsQL Sickle Cell Disease Module
Pediatric Quality of Life Inventory—Sickle Cell Disease Module · Also known as: PedsQL 3.0 Sickle Cell
The PedsQL Sickle Cell Disease Module is a disease-specific instrument developed by Varni et al. in 2012 to measure quality of life in children and adolescents with sickle cell disease aged 2–18 years. Measuring across domains including pain and symptoms, functional limitations, school impact, and disease-related worry, it captures how sickle cell disease and its complications affect daily life and well-being. Used alongside the PedsQL Generic Core Scales, it provides comprehensive assessment of sickle cell disease-specific and general health-related quality of life.
Read the full method
Sign in with a free account to read this section.
Method map
The neighbourhood of related methods — select a node to explore.
When to use it
The PedsQL Sickle Cell Disease Module is indicated for children and adolescents aged 2–18 years with a confirmed diagnosis of sickle cell disease (any genotype: HbSS, HbSC, HbS-thalassemia). It is particularly valuable in pediatric hematology clinics for comprehensive quality-of-life assessment alongside disease outcomes, in clinical trials evaluating disease-modifying therapies (hydroxyurea, voxelotor, gene therapy) or pain management strategies, in transition care planning for adolescents moving to adult hematology, and in comprehensive psychosocial assessment. The instrument is not appropriate for children without sickle cell disease or for sickle cell trait (asymptomatic carriers).
Strengths & limitations
- Comprehensive disease-specific assessment captures sickle cell disease-unique impacts (pain crisis burden, chronic symptoms, disease-related worry, school interference) that generic measures miss.
- Multi-domain structure identifies specific areas of disease burden, enabling targeted interventions (pain management, school support, psychosocial care).
- Parallel child and parent versions enable assessment of child experience and parental perception; discrepancies often reveal parental anxiety or protective overrestriction.
- Integrates with PedsQL Generic Core Scales for comprehensive QoL measurement spanning disease-specific and general functioning.
- Responsive to changes in disease status, pain crisis frequency, and treatment effectiveness.
- Validated across diverse sickle cell genotypes and ages 2–18 years; captures both acute and chronic impacts.
- No published MCID; clinically meaningful change thresholds must be estimated from related instruments or clinical judgment.
- Requires administration of both Sickle Cell Module and Generic Core Scales; total administration time is 15–20 minutes, which may be burdensome during routine clinic visits.
- Parent-child discrepancies are common, particularly in adolescents; interpretation can be ambiguous when perspectives diverge significantly.
- Limited normative data by sickle cell genotype or disease severity; interpretation relies on baseline-to-follow-up comparison or group means rather than population norms.
- Does not directly measure hemoglobin level, pain crisis frequency, or organ complications; must be paired with clinical and laboratory assessments.
Frequently asked
Should I use the PedsQL Sickle Cell Module alone or with the Generic Core Scales?
Use both. The Sickle Cell Module captures disease-specific impacts (pain, disease symptoms, disease worry), while the Generic Core Scales measure general health-related quality of life (physical, emotional, social, school functioning). Together, they provide comprehensive assessment. Using only the module may miss important impacts on school performance or peer relationships not directly related to sickle cell disease.
What is a clinically meaningful change on the PedsQL Sickle Cell Module?
There is no published MCID specific to the Sickle Cell Module. Based on other PedsQL modules, improvements of 5–10 points per scale are often considered clinically meaningful. However, clinical meaningfulness should be contextualized to the child's baseline score and clinical situation (e.g., a child improving from 45 to 55 following hydroxyurea initiation represents meaningful improvement).
Can I use the Sickle Cell Module for children with sickle cell trait (HbAS)?
No. The Sickle Cell Module is validated for sickle cell disease (HbSS, HbSC, HbS-thalassemia). Children with sickle cell trait are asymptomatic carriers and would not experience the disease burden that the module measures. Standard quality-of-life measures would be more appropriate if assessing anxiety or health perceptions in asymptomatic carriers.
What age range is the PedsQL Sickle Cell Module validated for?
Child self-report is validated for ages 5–18 years. Parent proxy is available for ages 2–18 years. For very young children (age 2–4), parent proxy is the only option. For adolescents (13–18), self-report is strongly preferred, though parent perspective remains valuable.
Sources
- Varni, J. W., Limbers, C. A., Bryant, W. P., & Wilson, D. P. (2012). The PedsQL in pediatric sickle cell disease: Measurement model, factor structure, and reliability and validity of the pediatric quality of life inventory sickle cell disease module. Journal of Health Psychology, 17(7), 1012-1024. link ↗
- Klingel, M., Kamps, R., Douwes Dekker, H. M., Grobbee, D. E., Hartman, A., & Moll, A. C. (2012). Sickle cell disease and quality of life. International Journal of Environmental Research and Public Health, 15(8), 1638. link ↗
How to cite this page
ScholarGate. (2026, June 3). Pediatric Quality of Life Inventory—Sickle Cell Disease Module. ScholarGate. https://scholargate.app/en/pediatric-medicine/pedsql-sickle-cell
Which method?
Set this method beside its closest kin and read them side by side — the library lays the books on the table; the choice is yours.
- PAQLQPediatric Medicine↔ compare
- PedsQL Cancer ModulePediatric Medicine↔ compare
- PedsQL Cardiac ModulePediatric Medicine↔ compare
- PedsQL Diabetes ModulePediatric Medicine↔ compare